Preventative Care in Scleroderma: What Is the Best Approach to Vaccination?

Leonardo Martin Calderon; Janet E Pope; Ami A Shah; Robyn T Domsic

doi:10.1016/j.rdc.2023.01.012

Preventative Care in Scleroderma: What Is the Best Approach to Vaccination?

Rheum Dis Clin North Am. 2023 May;49(2):401-410. doi: 10.1016/j.rdc.2023.01.012.

Authors

Leonardo Martin Calderon¹, Janet E Pope², Ami A Shah³, Robyn T Domsic⁴

Affiliations

¹ Department of Medicine, Schulich School of Medicine and Dentistry, University of Western Ontario, London, Ontario, Canada.
² Department of Medicine, Schulich School of Medicine and Dentistry, University of Western Ontario, London, Ontario, Canada; Division of Rheumatology, St. Joseph's Health Care, London, Ontario, Canada.
³ Division of Rheumatology, Johns Hopkins University School of Medicine, Johns Hopkins Scleroderma Center, Baltimore, MD, USA.
⁴ Division of Rheumatology and Clinical Immunology, University of Pittsburgh School of Medicine, 3500 Terrace Street, Pittsburgh, PA 15261, USA. Electronic address: rtd4@pitt.edu.

Abstract

Systemic sclerosis (SSc) is a rare multisystem autoimmune disease characterized by fibrosis, vasculopathy, and autoimmunity. There are multiple complications inherent to SSc and its management. One of these complications is increased infection risk, which can lead to decreased quality of life and increased morbidity and mortality. Patients with SSc have lower vaccination rates and decreased vaccine seroconversion secondary to immunosuppressive medications compared with the general population. The purpose of this review is to provide clinicians with an approach to vaccinations in SSc.

Keywords: Preventative medicine; Prevention; SARS-CoV-2; Scleroderma; Systemic sclerosis; Vaccination; Vaccines.

Publication types

Review
Research Support, N.I.H., Extramural

MeSH terms

Autoimmunity
Fibrosis
Humans
Quality of Life*
Scleroderma, Systemic* / complications
Vaccination / adverse effects

Abstract

Publication types

MeSH terms

Grants and funding